Efficacy of the combination of Curcuma Longa and standard triple therapy in the Helicobacter pylori eradication therapy compared with standard triple therapy with placebo: a multicenter, double-blind, randomized controlled clinical trial Helicobacter pylori, curcumin, turmeric, standard PPI base triple therapy
Conditions
Interventions
The first group was treated with turmeric (curcumin) 500 mg every 8 hours plus a standard dose PPI every 12 hours plus amoxicillin 1 g every 12 hours and clarithromycin 500 mg or metronidazole 500 mg
Experimental Drug,Placebo Comparator Drug
Standard PPI based triple therapy plus curcumin,Standard PPI based triple therapy plus placebo
Sponsors
None listed
Eligibility
Sex/Gender
All
Age
20 Years to No maximum
Inclusion criteria
Inclusion criteria: The inclusion criteria were that the patient's age was greater than 20 years. Patients were screened for H. pylori infection by upper gastrointestinal endoscopy in combination with a rapid urease test (CLO test). If the rapid urease test was positive (CLO positive), biopsy results and special dyes for H. pylori were found in the gastrointestinal endoscopy departments of Phramongkutklao Hospital and Ananda Mahidol Hospital from August 1, 2021, to January 31, 2023. Participants who consent to the research.
Exclusion criteria
Exclusion criteria: Exclusion criteria were patients with an allergy to a drug used in the research, pregnant or lactating women, individuals with a history of treatment for H. pylori infection, patients in critically illed patients, patients with diseases that could shorten the life of study participants or increase the risk of participation in the study, such as cancer, infectious diseases (HIV, infectious tuberculosis), heart disease, severe lung disease, end-stage renal disease, severe liver disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy of the eradication rate of Helicobacter pylori infection with curcumin plus 14 days of standard PPI- based triple therapy versus a standard PPI- based triple therapy. 1 month after intervention Clo test, Serologic test for HP, Urea breath te, Stool antigen test | — |
Secondary
| Measure | Time frame |
|---|---|
| Study for rescued abdominal pain before and after treatment, Side effects in both groups 2-4 weeks after intervention VAS pain score (0-10) | — |
Countries
Thailand
Contacts
Public ContactVutthikorn Khingmontri
Phramongkutklao hospital
Outcome results
None listed